Home/Pipeline/Undisclosed Partnered Program

Undisclosed Partnered Program

Undisclosed

DiscoveryPartnered

Key Facts

Indication

Undisclosed

Phase

Discovery

Status

Partnered

Company

Septerna

About Septerna

Septerna leverages its industrial-scale Native Complex Platform® to unlock previously difficult-to-drug GPCRs, a target class accounting for one-third of all FDA-approved drugs but with 75% of its therapeutic potential still untapped. The company has built a wholly-owned pipeline of oral small molecule programs, with its lead asset SEP-631 (MRGPRX2 NAM) showing positive Phase 1 data and entering Phase 2 for chronic spontaneous urticaria. Septerna's strategy combines independent development of programs in endocrinology and immunology with selective partnerships for metabolic programs, positioning it to develop the next generation of impactful GPCR-targeted medicines.

View full company profile

Therapeutic Areas

Endocrinology Immunology and Inflammation Metabolic Diseases Neurology Women's Health Cardiovascular Disease Respiratory Disease

Other Undisclosed Drugs

Drug	Company	Phase	Status
ASPEN Study Program	Insmed	Phase 3	Completed
ARISE Study Program	Insmed	Phase 3	Completed
MGL-2086	Madrigal Pharmaceuticals	Phase 1	Expected 2Q26
Innovative Proprietary/Licensed Products	Laboratorios Farmaceuticos Rovi	Various	Active
Undisclosed Cell Therapy	Immix Biopharma	Pre-clinical	Early-stage
HTL0039732	Nxera Pharma	Preclinical	Active
LYT-310	PureTech Health	Preclinical	Active
Bispecific (Undisclosed)	MacroGenics	Preclinical	Active
Sec61 Portfolio Assets	Kezar Life Sciences	Preclinical	Acquired by Enodia Therapeutics
WTX-518	Werewolf Therapeutics	Preclinical	Discovery/Preclinical
WTX-712	Werewolf Therapeutics	Preclinical	Discovery/Preclinical
Measovir®-based Prophylactic Vaccine (with Unither)	Oncovita	Research/Pre-clinical	Early-stage collaboration